Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study aims to assess biomarkers and their related polymorphisms in the context of
cancer-associated thromboembolism, with a particular focus on their interaction with the
immune system. The roles of immune checkpoints, inflammatory and angiogenesis factors, as
well as circulating immune cells will be elucidated. Additionally, our investigation extends
to the exploration of long non-coding RNAs (LncRNAs) and genes associated with the
coagulation vascular system. Initially, these aspects will be evaluated in the context of
colorectal cancer, with the intention to expand our research to other solid tumors.
The identification of these biomarkers and genetic factors holds the potential to
revolutionize therapeutic approaches for patients with cancer-associated thromboembolism,
shedding light on their chemotherapy resistance. The effectiveness of combining immunotherapy
with targeted inhibitors like Palbociclib and anticoagulants such as Rivaroxaban, among other
potential interventions, will be assessed.
This study aims to make significant contributions to the understanding of these critical
aspects, ultimately leading to the development of more effective treatment strategies for
cancer patients.